acetovanillone has been researched along with Parkinsonian Disorders in 3 studies
apocynin : An aromatic ketone that is 1-phenylethanone substituted by a hydroxy group at position 4 and a methoxy group at position 3.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Mito-Apo showed excellent brain bioavailability and also markedly attenuated MPTP-induced oxidative markers in the substantia nigra (SN)." | 1.43 | Mitoapocynin Treatment Protects Against Neuroinflammation and Dopaminergic Neurodegeneration in a Preclinical Animal Model of Parkinson's Disease. ( Anantharam, V; Brenza, T; Ghosh, A; Harischandra, DS; Jin, H; Joseph, J; Kalyanaraman, B; Kanthasamy, A; Kanthasamy, AG; Langley, MR; Narasimhan, B; Neal, ML, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Philippens, IH | 1 |
| Wubben, JA | 1 |
| Finsen, B | 1 |
| 't Hart, BA | 1 |
| Ghosh, A | 1 |
| Langley, MR | 1 |
| Harischandra, DS | 1 |
| Neal, ML | 1 |
| Jin, H | 1 |
| Anantharam, V | 1 |
| Joseph, J | 1 |
| Brenza, T | 1 |
| Narasimhan, B | 1 |
| Kanthasamy, A | 1 |
| Kalyanaraman, B | 1 |
| Kanthasamy, AG | 1 |
| Kumar, A | 1 |
| Singh, BK | 1 |
| Ahmad, I | 1 |
| Shukla, S | 1 |
| Patel, DK | 1 |
| Srivastava, G | 1 |
| Kumar, V | 1 |
| Pandey, HP | 1 |
| Singh, C | 1 |
3 other studies available for acetovanillone and Parkinsonian Disorders
| Article | Year |
|---|---|
Oral treatment with the NADPH oxidase antagonist apocynin mitigates clinical and pathological features of parkinsonism in the MPTP marmoset model.
Topics: Acetophenones; Administration, Oral; Animals; Callithrix; Enzyme Inhibitors; Female; Male; NADPH Oxi | 2013 |
Mitoapocynin Treatment Protects Against Neuroinflammation and Dopaminergic Neurodegeneration in a Preclinical Animal Model of Parkinson's Disease.
Topics: Acetophenones; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Cel | 2016 |
Involvement of NADPH oxidase and glutathione in zinc-induced dopaminergic neurodegeneration in rats: similarity with paraquat neurotoxicity.
Topics: Acetophenones; Acetylcysteine; Animals; Apoptosis; Caspases; CD11b Antigen; Corpus Striatum; Cytochr | 2012 |